Welcome to our dedicated page for Nano-X Imaging Ltd. news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on Nano-X Imaging Ltd. stock.
NANO-X IMAGING LTD (Nanox) (NASDAQ: NNOX) is a medical imaging technology company that combines imaging hardware, AI-based software, cloud infrastructure, and teleradiology services. The Nanox news feed on this page aggregates company press releases and market updates so readers can follow how Nanox advances its imaging platform, commercial strategy, and capital markets activity over time.
Nanox’s recent news highlights its Nanox.ARC and Nanox.ARC X multi-source digital tomosynthesis systems, including CE Mark certification for Nanox.ARC in Europe and FDA 510(k) clearance for Nanox.ARC X for general use in multiple clinical indications. Articles also cover distribution agreements and collaborations with partners in countries such as France, the Czech Republic, Greece, Romania, Serbia, Montenegro, and Bosnia and Herzegovina, reflecting efforts to expand clinical and commercial deployment of its imaging solutions.
Another key news theme is the growth of Nanox.AI and its imaging analytics portfolio. Press releases describe AI algorithms that analyze routine CT scans for early signs associated with chronic diseases and bone health solutions such as HealthVCF and HealthOST, which have been included in an Early Value Assessment by the UK National Institute for Health and Care Excellence. Updates also discuss acquisitions like VasoHealthcare IT, intended to support deployment of AI solutions across U.S. healthcare facilities.
Investors and analysts can also find financial results announcements, guidance updates, and details of registered direct offerings and other financings, as reported in Nanox’s press releases and related SEC filings. Together, these news items provide insight into Nanox’s commercialization progress, clinical collaborations, AI development roadmap, and capital strategy. Bookmark this page to access an organized stream of Nanox news, from product and partnership updates to financial and regulatory disclosures.
Nanox (NASDAQ: NNOX) announced on March 3, 2026 that Nanox Impact signed a distribution agreement with Imperial Imaging Technology to deploy the Nanox.ARC multisource digital tomosynthesis system across Georgia, Alabama, Tennessee, North Carolina, South Carolina, and Northern Florida.
Imperial will handle marketing, demos, clinical evaluations, installations, and customer support for orthopedic and musculoskeletal practices. According to the company, Nanox.ARC DTS imaging is reimbursable under an existing CPT code and requires no pre-authorization.
Nanox (Nasdaq: NNOX) announced an exclusive distribution agreement with Intec SRL for the Nanox.ARC digital tomosynthesis system in Argentina, dated Feb 19, 2026. Intec will manage marketing, distribution, installation, clinical evaluations, training and local support.
Commercial sales in Argentina are subject to required regulatory approvals; Intec will provide technical support and post-warranty service.
Nanox (Nasdaq: NNOX) will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time and present new AI capabilities at ECR 2026 (March 4-8, Vienna).
The company will demonstrate TAP2D image enhancement, present ADOPT study data, and highlight FDA-cleared and CE-marked AI solutions for cardiac, bone and liver analysis.
Nanox (NNOX) announced FDA 510(k) clearance on February 3, 2026 for TAP2D, a cloud-enabled image enhancement for Nanox.ARC and Nanox.ARC X tomosynthesis systems. The feature generates a clear 2D view from a single tomosynthesis scan without additional radiation and integrates into existing workflows.
The clearance advances Nanox's regulatory pathway toward removing adjunct use in the US and enables remote software upgrades to existing installations as part of the company's rollout of imaging improvements.
Nanox (Nasdaq: NNOX) announced an exclusive distribution agreement with Adriamed to commercialize the Nanox.ARC digital tomosynthesis system in Serbia, Montenegro, and Bosnia and Herzegovina on January 14, 2026.
The Nanox.ARC holds a CE Mark for its intended use and Adriamed will handle marketing, distribution, installation, and support across the Western Balkans. The collaboration follows recent European agreements in Greece, Romania, Czech Republic, and France and aims to expand access to lower-cost 3D imaging for regional healthcare providers.
Nanox (Nasdaq: NNOX) announced a distribution collaboration with Althea France to introduce the CE-marked Nanox.ARC multi-source digital tomosynthesis system across France.
Althea France, part of the Althea Group that manages thousands of imaging devices, will lead market introduction, sales and service and leverage relationships with university hospitals, public hospitals and private clinics. This deal is Nanox's fourth European distribution agreement following partnerships in Greece, Romania and the Czech Republic. The Nanox.ARC is cleared for commercialization across the European Union following CE Mark certification.
Nanox (Nasdaq: NNOX) announced that its deep‑learning subsidiary Nanox.AI had two bone‑analysis tools — HealthVCF and the upgraded HealthOST — recommended by NICE for inclusion in an Early Value Assessment in UK NHS hospitals for a three‑year evidence‑generation period beginning November 24, 2025.
The tools will be assessed for their ability to support opportunistic detection of vertebral fragility fractures on X‑rays and CT scans, be compared with current NHS standard of care, and are eligible for core NHS funding while evidence is gathered. Two of five AI bone solutions in the assessment are from Nanox.AI.
Nanox (Nasdaq: NNOX) announced a registered direct offering of 3,826,530 ordinary shares expected to raise gross proceeds of approximately $15 million before offering expenses. The closing is expected on or about November 25, 2025, subject to customary closing conditions. The company said it intends to use net proceeds for working capital and general corporate purposes. Titan Partners Group is acting as sole placement agent. The offering is made under an effective Form F-3 shelf registration that became effective May 5, 2023, and will be described in a prospectus supplement filed with the SEC.
Nanox (NASDAQ:NNOX) reported third-quarter 2025 results and a business update on November 20, 2025. The company generated $3.4M revenue in Q3 2025 versus $3.0M year-ago, and reported a GAAP net loss of $13.7M for the quarter. Gross loss was $2.9M (GAAP) and non-GAAP gross loss was $0.3M. Nanox completed the acquisition of Vaso Healthcare IT, added clinical sites including Cedars-Sinai and Olympe Imagerie, and signed European ARC distribution partnerships. Cash and equivalents totaled $55.5M as of September 30, 2025, and the company expects >100 deployed units by year-end 2025 and $35M revenue for 2026.
Nanox (Nasdaq: NNOX) agreed to acquire VasoHealthcare IT Inc. from Vaso (OTCQX: VASO) to accelerate U.S. deployment of its AI imaging solutions. The transaction is expected to close within a couple of weeks and integrates VHC IT’s implementation, systems integration, workflow optimization, data migration, user training, and nationwide go-live support with Nanox.AI’s FDA-cleared CT-scan AI tools.
Consideration is up to $800,000: $200,000 cash at closing plus up to $600,000 in performance-based earnouts over two years contingent on revenue retention of existing customers.